

Review Article***Neoplasia*: The Second Decade****Alnawaz Rehemtulla**

University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200, USA

Abstract

This issue marks the end of the 10-year anniversary of *Neoplasia* where we have seen exciting growth in both number of submitted and published articles in *Neoplasia*. *Neoplasia* was first published in 1999. During the past 10 years, *Neoplasia* has dynamically adapted to the needs of the cancer research community as technologies have advanced. *Neoplasia* is currently providing access to articles through PubMed Central to continue to facilitate rapid broad-based dissemination of published findings to the scientific community through an Open Access model. This has in part helped *Neoplasia* to achieve an improved impact factor this past year, demonstrating that the manuscripts published by *Neoplasia* are of great interest to the overall cancer research community. This past year, *Neoplasia* received a record number of articles for review and has had a 21% increase in the number of published articles.

Neoplasia (2008) 10, 1314–1324**Overview**

During the past 3 years (2006–2008), *Neoplasia* has shown strong growth as evidenced in the number of articles published. As shown in Figure 1, the percentage of articles published in *Neoplasia* increased




Figure 1. A plot of the percent increase in the number of articles published in *Neoplasia* from 2006 to 2008. For each year, the bar graph indicates the percentage increase over the prior year. Note a major jump in the percentage of published articles occurred in 2008, which was 21% more than that in the previous year.

by 6% in 2007 and further increased by an astounding 21% in 2008. Manuscripts published in these pages continue to be of the utmost high quality and cover a broad range of research topics and reviews from many different and exciting areas of cancer research. Shown in Table 1 are examples of articles previously published which have been sorted by general topic area for the 2006–2008 publication time frame. Whereas many articles could be classified in several of these categories, it is evident that *Neoplasia* provides its readership with a broad coverage of the many exciting discoveries during the past year.

Neoplasia continues to differentiate itself from other journals in many areas. One key example is that *Neoplasia* provides immediate open access to all of its published articles at the time of publication through PubMed Central. This policy allows for all of the articles published by *Neoplasia* to be accessible immediately to the worldwide cancer research communities and to patients interested in keeping up-to-date with the latest developments, which may affect their treatment decisions. This feature also provides authors' research findings available to the largest possible readership ensuring that articles published in *Neoplasia* will have significant impact. One metric of the success of Open Access can be found in the Thomson Scientific Impact Factor, which, for *Neoplasia*, has increased from 4.9 in 2006 to 5.7 in 2007, revealing both the high quality and impact of articles

Address all correspondence to: Alnawaz Rehemtulla, PhD, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48109-2200. E-mail: alnawaz@umich.edu
Received 27 October 2008; Revised 27 October 2008; Accepted 27 October 2008

Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/\$25.00
DOI 10.1593/neo.81372

Table 1. Major Research Topics of Publications in *Neoplasia* from 2006 to 2008.

Subject	2006	2007	2008
Cancer genetics	[18,21,29,31,37,45,47,50,51,68,76,89,99,100,108,111,117]	[128,133,135,136,137,138,140,141,143,150,166,174,176,183,196,197,204,205,223,225,227,232,241]	[243,245,249,266,267,268,272,288,296,303,306,307,312,315,319,331,332,333,345,350,352,357,361,365,367,370,381,388,389,391]
Cell and tumor biology	[4,5,10,11,13,16,17,27,28,32,33,36,48,55,59,60,62,63,65,67,69,70,71,72,73,74,78,80,82,84,87,88,92,98,104,105,106,107,110,115,116]	[119,121,122,127,130,134,142,145,147,149,151,154,155,157,162,163,164,169,175,177,181,182,184,185,188,190,191,192,194,195,199,200,202,203,207,208,212,214,215,218,222,224,230,234,235,237,240]	[244,251,252,256,257,258,259,260,261,262,266,269,274,281,284,289,291,293,295,298,299,301,302,311,316,318,320,321,324,325,327,334,339,340,342,344,349,356,358,359,363,369,371,375,378,379,380,382,384,385]
Experimental therapeutics	[1,2,3,9,12,19,35,42,43,44,49,52,58,79,81,85,96,97,102,103,112]	[129,131,144,148,153,158,165,170,171,172,186,187,193,198,206,209,211,219,221,229,233,236,238]	[246,247,248,264,265,271,276,277,285,290,292,305,308,313,317,322,323,328,335,336,338,346,353,354,366,368,374,376,383,387]
Tumor immunology	[22,26,77,90,101]	[161,179]	[253,275,287,330,341,343,355,367]
Epidemiology and prevention	[6,7,8,14,15,20,41,75,113]	[139,152]	[279,283,326,362,373,377]
Cancer imaging	[23,24,25,30,34,38,39,54,57,61,64,66,83,86,91,109]	[124,132,159,160,167,178,189,201,213,216,226,228,231,239]	[263,273,278,282,286,294,309,314,347,351]
Clinical investigations	[94,95,114]	[118,120,126,146,173,217,242]	[250,255,297,304,310,348,360]
Endocrinology	[93]	[125]	[270,337,364]
Animal models	[53,56]	[168,210,220]	[254,280,300,329,372,386]
Angiogenesis	[40,46]	[123,156,180]	[331,390]

published by *Neoplasia* and the increased impact in the cancer field as judged by the escalating number of citations by other scientists.

In conclusion, *Neoplasia* has successfully adapted to the needs of the cancer research community by implementing leading-edge technological changes including online peer review and electronic hosting of articles on PubMed Central, which now provides for instant and Open Access for all articles published within our pages.

References

- Klein PJ, Schmidt CM, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, and Sebolt-Leopold JS (2006). The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. *Neoplasia* **8**, 1–8.
- Andriani F, Perego P, Carenini N, Sozzi G, and Roz L (2006). Increased sensitivity to cisplatin in non-small lung cancer cell lines after *FHIT* gene transfer. *Neoplasia* **8**, 9–17.
- Kiewlich D, Zhang J, Gross C, Xia W, Larsen B, Cobb RR, Biroc S, Gu J, Sato T, Light DR, et al. (2006). Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. *Neoplasia* **8**, 18–30.
- Watson GA, Queiroz de Oliveira PE, Stang MT, Armstrong MJ, Gooding WE, Kuan S, Yim JH, and Hughes SJ (2006). Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. *Neoplasia* **8**, 31–37.
- Chekerov R, Klamann I, Zafrakas M, Koensgen D, Mustea A, Petschke B, Lichtenegger W, Schouli JJ, and Dahl E (2006). Altered expression pattern of topoisomerase II α (TOP2A) in ovarian tumor epithelial and stromal cells after platinum-based chemotherapy. *Neoplasia* **8**, 38–45.
- Liu Y, Lan Q, Siegfried JM, Luketich JD, and Keohavong P (2006). Aberrant promoter methylation of *p16* and *MGMT* genes in lung tumors from smoking and never-smoking lung cancer patients. *Neoplasia* **8**, 36–51.
- Yan Y, Wang Y, Tan Q, Hara Y, Yun T, Lubet R, and You M (2006). Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. *Neoplasia* **8**, 52–58.
- Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, et al. (2006). Defining aggressive prostate cancer using a 12 gene model. *Neoplasia* **8**, 59–68.
- Loberg RD, Day LL, Dunn R, Kalikin LM, and Pienta KJ (2006). Inhibition of decay accelerating factor (CD55) attenuates prostate cancer growth and survival *in vivo*. *Neoplasia* **8**, 69–78.
- Goon P, Lip G, Boos C, Stonelake P, and Blann A (2006). Circulating endothelial cells and endothelial progenitor cells in cancer. *Neoplasia* **8**, 79–88.
- Hofmann M, Guschel M, Bernd A, Bereiter-Hahn J, Kaufmann R, Tandl C, Wiig H, and Kippenberger S (2006). Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. *Neoplasia* **8**, 89–95.
- Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D, Giavazzi R, Pavan A, and Dolo V (2006). Bioavailability of VEGF in tumor shed vesicles depends on vesicle burst induced by acidic pH. *Neoplasia* **8**, 96–103.
- Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, and Kiupel M (2006). The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. *Neoplasia* **8**, 104–111.
- Kelavkar UP, Hutzley J, Dhir R, Kim P, Allen KG, and McHugh K (2006). Prostate tumor growth and recurrence can be modulated by the omega (ω)-6: ω -3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. *Neoplasia* **8**, 112–124.
- Liu Y, Zhang W, Niu T, Cheung LH, Munshi A, Meyn RE, and Rosenblum MG (2006). Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity and radiosensitivity. *Neoplasia* **8**, 125–135.
- Tabori U, Vukovic B, Zielenska M, Hawkins C, Braude I, Rutka J, Bouffert E, Squire J, and Malkin D (2006). The role of telomere maintenance in the spontaneous growth arrest pediatric low grade gliomas. *Neoplasia* **8**, 136–142.
- Thews O, Gassner B, Kelleher DK, Schwerdt G, and Gekle M (2006). Impact of extracellular acidity on the activity of p-glycoprotein and the cytotoxicity of chemotherapeutic drugs. *Neoplasia* **8**, 143–152.
- Tomlins L, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening EE, Makarov V, and Chinnaiyan AM (2006). Whole transcriptome amplification for gene expression profiling and development of molecular archives. *Neoplasia* **8**, 153–162.
- Wolter KG, Wang SJ, Henson BS, Wang S, Griffith KA, Kumar B, Chen J, Carey TE, Bradford CR, and D'Silva NJ (2006). (-)-Gossypol inhibits growth of human head and neck squamous cell carcinoma *in vivo*. *Neoplasia* **8**, 163–172.
- Lo AK, Lo K, Tsao S, Wong H, Hui J, To K, Hayward S, Chui Y, Lau Y, Takada K, et al. (2006). Epstein-Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. *Neoplasia* **8**, 173–180.
- Wu Z, Siadaty MS, Riddick G, Frierson HF Jr, Lee JK, Golden W, Knuutila S, Hampton GM, El-Rifai W, and Theodorescu D (2006). A novel method for gene expression mapping of metastatic competence in human bladder cancer. *Neoplasia* **8**, 181–189.
- Ghebeh H, Mohammed S, Al-Omar A, Qattan A, Lehe C, Al-Qudaihi G, Elhum N, Alshabanah M, Bin Amer S, Tulbah A, et al. (2006). The B7-H1 (PD-L1) T lymphocytes inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high risk prognostic factors. *Neoplasia* **8**, 190–198.
- McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, Kelland LR, and Robinson S (2006). Rat tumor response to the vascular disrupting agent 5,6-dimethylxanthene-4-acetic acid (DMXAA) as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindole acetic acid levels, and tumor necrosis. *Neoplasia* **8**, 199–206.
- Gimi B, Mori N, Ackerstaff E, Frost EE, Bulte JW, and Bhujwala ZM (2006). Noninvasive MR imaging of endothelial cell response to human breast cancer cells. *Neoplasia* **8**, 207–213.

- [25] Montet X, Montet-Abou K, Reynolds F, Weissleder R, and Josephson L (2006). Nanoparticle imaging of integrins on tumor cells. *Neoplasia* **8**, 214–222.
- [26] Gros F, Yasmine S, de Guibert S, Branger B, Bernard M, Fauchet R, and Amiot L (2006). Soluble HLA-G molecules are increased during acute leukaemia especially in subtypes affecting monocytic and lymphoid lineages. *Neoplasia* **8**, 223–230.
- [27] Oba Shinjo SM, Correa M, Ricca TI, Molognoni F, Pinhal MA, Neves IA, Marie SK, Sampaio LO, Nader HB, Chammas R, et al. (2006). Melanocyte transformation associated with substrate adhesion impediment. *Neoplasia* **8**, 231–242.
- [28] Leung Y, Gao Y, Lau K, Zhang X, and Ho S (2006). ICI 182,780-regulated gene expression in DU145 prostate cancer cells is mediated via estrogen receptor- β /NF κ B crosstalk. *Neoplasia* **8**, 242–249.
- [29] Duriseti KS, Winnard PT Jr, Mironchik Y, Vesuna F, Raman A, and Raman V (2006). HOXA5 regulates hMLH1 expression in breast cancer cells. *Neoplasia* **8**, 250–258.
- [30] Moffat BA, Chenevert TL, Meyer C, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, and Ross BD (2006). The functional diffusion map: an imaging biomarker for early prediction of cancer treatment outcome. *Neoplasia* **8**, 259–267.
- [31] Kwong J, Lee J, Wong K, Zhou X, Wong D, Lo K, Welch WR, Berkowitz RS, and Mok SC (2006). Candidate tumor suppressor gene *DLEC1* is frequently down-regulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. *Neoplasia* **8**, 268–278.
- [32] Zeng G, Germinaro M, Micsenyi A, Monga NK, Bell A, Sood A, Malhotra V, Sood N, Midda V, Monga DK, et al. (2006). Aberrant Wnt/ β -catenin signaling in pancreatic adenocarcinoma. *Neoplasia* **8**, 279–289.
- [33] Engl T, Relja B, Marian D, Blumenberg C, Mueller I, Beecken W, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D, et al. (2006). CXCR4 chemokine receptor mediates prostate tumor cell adhesion via α_5 and β_3 integrins. *Neoplasia* **8**, 290–301.
- [34] Trehin R, Figueiredo J, Pittet M, Weissleder R, Josephson L, and Mahmood U (2006). Fluorescent nanoparticle uptake for brain tumor visualization. *Neoplasia* **8**, 302–311.
- [35] Taras D, Blanc J, Rullier A, Dugot-Senart N, Laurendeau I, Bièche I, Pines M, and Rosenbaum J (2006). Halofuginone suppresses lung metastasis of chemically-induced hepatocellular carcinoma in rats via MMP inhibition. *Neoplasia* **8**, 312–318.
- [36] Kuefer R, Day KC, Kleer CG, Sabel MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, and Day ML (2006). The ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. *Neoplasia* **8**, 319–329.
- [37] Goldstein M, Meller I, Issakov J, and Orr-Urtreger A (2006). Novel genes implicated in embryonal, alveolar and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. *Neoplasia* **8**, 332–343.
- [38] Tsarfay G, Stein GY, Moshitch-Moshkovitz S, Kaufman DW, Cao B, Resau JH, Vande Woude GE, and Tsarfay I (2006). HGF/SF increases tumor blood volume: a novel tool for *in vivo* functional molecular imaging of Met. *Neoplasia* **8**, 344–352.
- [39] Moshitch-Moshkovitz S, Tsarfay G, Kaufman DW, Stein GY, Shichrur K, Resau JH, Vande Woude G, and Tsarfay I (2006). *In vivo* direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. *Neoplasia* **8**, 353–391.
- [40] Olsen MW, Ley CD, Junker N, Hansen AJ, Lund EL, and Kristjansen PE (2006). Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure. *Neoplasia* **8**, 362–372.
- [41] Pérez-Carreón JI, López-García C, Fattel-Fazenda S, Arce-Popoca E, Alemán-Lazarini L, Hernández-García S, Le Berre V, Sokol S, Francois J, and Villa-Treviño S (2006). Gene expression profile related to the progression of preneoplastic nodules toward hepatocellular carcinoma in rats. *Neoplasia* **8**, 373–383.
- [42] Liu Y, Zhang W, Cheung LH, Wu Q, Li C, Van Pelt CS, and Rosenblum MG (2006). The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. *Neoplasia* **8**, 384–393.
- [43] Wan X, Shen N, Mendoza A, Khanna C, and Helman LJ (2006). CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to targeting mTOR/Hif-1 α /VEGF signaling. *Neoplasia* **8**, 394–402.
- [44] Mijatovic T, Mathieu V, Gausin J, De Nève N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F, and Kiss R (2006). Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. *Neoplasia* **8**, 403–412.
- [45] Jin Y, Mertens F, Kullendoreff CM, and Panagopoulos I (2006). Fusion of the tumor suppressor gene *CHEK2* and the gene for the regulatory subunit B of protein phosphatase 2 (*PPP2R2A*) in a childhood teratoma. *Neoplasia* **8**, 413–418.
- [46] Lee O, Fueyo J, Xu J, Yung W, Lemoine MG, Lang FF, Bekele B, Zhou X, Alonso MA, Aldape KD, et al. (2006). Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. *Neoplasia* **8**, 419–428.
- [47] Furth EE, Gustafson KS, Dai C, Gibson SL, Menard-Katcher P, Chen T, Koh J, and Enders GH (2006). Induction of the tumor suppressor p16^{Ink4a} within regenerating crypts in ulcerative colitis. *Neoplasia* **8**, 429–436.
- [48] Schmidt CM, Crowell PL, Yip-Schneider M, Savage JJ, Hertzler DA II, and Cummings WO (2006). Cyclooxygenase-2 expression throughout hamster and human pancreatic neoplasia. *Neoplasia* **8**, 437–445.
- [49] Ziauddin M, Yeow W, Maxhimer JB, Baras A, Chua A, Reddy RM, Tsai W, Cole GW Jr, Schrupp DS, and Nguyen DM (2006). Valproic acid, an anti-epileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells via mitochondria-dependent caspase activation. *Neoplasia* **8**, 446–457.
- [50] Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, and Fuchs CS (2006). Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer. *Neoplasia* **8**, 458–464.
- [51] Yoshimoto M, Joshua A, Chilton-MacNeill S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, and Squire JA (2006). Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates genomic microdeletion of chromosome 21 is associated with rearrangement. *Neoplasia* **8**, 465–469.
- [52] Baker CH, Pino MS, and Fidler IJ (2006). Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors. *Neoplasia* **8**, 470–476.
- [53] van Laarhoven HW, Gambarota G, Lok J, Lammens M, Kamm YL, Wagener T, Punt CJ, Van der Kogel AJ, and Heerschap A (2006). Carbogen breathing differentially enhances blood plasma volume and 5-fluorouracil uptake in two murine colon tumor models with a distinct vascular structure. *Neoplasia* **8**, 477–487.
- [54] Corbin IR, Li H, Chen J, Lund-Katz S, Zhou R, Glickson JD, and Zheng G (2006). Low density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. *Neoplasia* **8**, 488–498.
- [55] Brehm R, Rüttinger C, Fischer P, Gashaw I, Winterhager E, Kliesch S, Bohle RM, Steger K, and Bergmann M (2006). Transition from pre-invasive carcinoma *in situ* to seminoma is accompanied with a reduction of connexin43-expression in Sertoli cells and germ cells. *Neoplasia* **8**, 499–509.
- [56] Kelavkar UP, Parwani A, Shappell SB, and Martin W (2006). Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. *Neoplasia* **8**, 510–522.
- [57] Garcia GE, Arevalo N, Bhaskaran S, Gupta A, Kyprianou N, and Kumar A (2006). Akt and CREB mediated prostate cancer cell proliferation inhibition by *NexrutineR* a *Phellodendron amurense* extract. *Neoplasia* **8**, 523–533.
- [58] Seshadri M, Mazurchuk R, Sperryak JA, Bhattacharya A, Rustum YM, and Bellnier DA (2006). Activity of the vascular disrupting agent 5,6-dimethylxanthone-4-acetic acid (DMXAA) against human head and neck carcinoma xenografts. *Neoplasia* **8**, 534–542.
- [59] Weihua Z, Tsan R, Nam D, Lu W, and Fidler IJ (2006). Loss of adhesion in the circulation converts amelanotic metastatic melanoma cells to become melanotic by inhibition of AKT. *Neoplasia* **8**, 543–550.
- [60] Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst A, Sigrist B, Kurtz S, Zangemeister-Wittke U, and Stahel R (2006). p53-Induced apoptosis occurs in the absence of p14^{ARF} in malignant pleural mesothelioma. *Neoplasia* **8**, 551–559.
- [61] Madhu B, Waterton JC, Griffiths JR, Ryan AJ, and Robinson S (2006). The response of RIF-1 fibrosarcomas to the vascular disrupting agent ZD6126 assessed by *in vivo* and *ex vivo* ¹H magnetic resonance spectroscopy. *Neoplasia* **8**, 560–567.
- [62] Li H, Goswami PC, and Domann F (2006). AP-2 γ induces p21 expression, arrests cell cycle, and inhibits tumor growth of human carcinoma cells. *Neoplasia* **8**, 569–577.
- [63] Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, and Pienta KJ (2006). CCL2 (monocyte chemoattractant protein-1) is a potent regulator of prostate cancer cell migration and proliferation. *Neoplasia* **8**, 578–586.
- [64] Thomas CD, Walczak C, Kaffy J, Pontikis R, Jouanneau J, and Volk A (2006). Early effects of combretastatin-A-4-P assessed by anatomical and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice. *Neoplasia* **8**, 587–595.
- [65] Reiland J, Kempf D, Roy M, Denkins Y, and Marchetti D (2006). FGF2 binding, signaling and angiogenesis are modulated by heparanase in metastatic melanoma cancer. *Neoplasia* **8**, 596–606.
- [66] Hama Y, Urano Y, Koyama Y, Kamiya M, Bernardo M, Paik R, Krishna MC, Choyke PL, and Kobayashi H (2006). *In vivo* spectral fluorescence imaging of

- submillimeter peritoneal cancer implants using a lectin-targeted optical agent. *Neoplasia* **8**, 607–612.
- [67] Schaefer K, Brachwitz K, Braun Y, Diallo RI, Wai DH, Zahn S, Schneider DT, Kuhn C, Vollmann A, Brockhoff G, et al. (2006). Constitutive activation of neuregulin/ERBB3 signaling pathway in clear cell sarcoma of soft tissue. *Neoplasia* **8**, 613–622.
- [68] Ohh M (2006). Ubiquitin pathway in VHL cancer syndrome. *Neoplasia* **8**, 623–629.
- [69] Dai M, Jin Y, Gallegos JR, and Lu H (2006). Balance of yin and yang: ubiquitylation-mediated regulation of p53 and c-Myc. *Neoplasia* **8**, 630–644.
- [70] Sun Y (2006). E3 ubiquitin ligases as cancer targets and bio-markers. *Neoplasia* **8**, 645–654.
- [71] Watson IR and Irwin MS (2006). Ubiquitin and ubiquitin-like modifications of the p53 family. *Neoplasia* **8**, 655–666.
- [72] Cheng J, Lee P, Bawa T, Gong L, and Yeh ET (2006). Role of de-sumoylation in the development of prostate cancer. *Neoplasia* **8**, 667–676.
- [73] Izzi L and Artisano L (2006). Ubiquitin-dependent regulation of TGF β signaling in cancer. *Neoplasia* **8**, 677–688.
- [74] Burger A, Amemiya Y, Kitching R, and Seth AK (2006). Novel RING E3 ubiquitin ligases in breast cancer. *Neoplasia* **8**, 689–695.
- [75] Cheung S, Liu C, Chow J, Lee Y, Ip Y, Ho J, and Fan S (2006). Preoperative plasma transcript AA454543 level is an independent prognostic factor for hepatocellular carcinoma after partial hepatectomy. *Neoplasia* **8**, 696–701.
- [76] von Rahden B, Stein HJ, Puehringer-Oppermann F, and Sarbia M (2006). c-myc Amplification is frequent in esophageal adenocarcinoma and correlated with up-regulation of VEGF-A expression. *Neoplasia* **8**, 702–707.
- [77] Borowsky AD, Dingley KH, Ubick EA, Turteltaub KW, Cardiff RD, and deVere White RW (2006). Inflammation and atrophy precede prostate neoplasia in PhIP induced rat model. *Neoplasia* **8**, 708–715.
- [78] Liu C, Chen Z, Chen Z, Zhang T, and Lu Y (2006). Multiple tumor types might originate from bone marrow-derived cells. *Neoplasia* **8**, 716–724.
- [79] Akhavan A, McHugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, Nelson JB, and Pflug B (2006). Endothelin receptor A blockade enhances taxane effects in prostate cancer. *Neoplasia* **8**, 725–732.
- [80] Squarize CH, Castilho RM, Sriuranpong V, Pinto DS Jr, and Gutkind JS (2006). A molecular cross-talk between the NF κ B and STAT3 signaling pathways in head and neck squamous cell carcinoma. *Neoplasia* **8**, 733–746.
- [81] Rebhun RB, Langley RR, Yokoi K, Fan D, Gershenwald JE, and Fidler IJ (2006). Targeting receptor tyrosine kinase on lymphatic endothelial cells for therapy of colon cancer lymph node metastasis. *Neoplasia* **8**, 747–757.
- [82] Glunde K, Jie C, and Bhujwalla ZM (2006). Mechanisms of indomethacin-induced alterations in choline phospholipid metabolism of breast cancer cells. *Neoplasia* **8**, 758–771.
- [83] Newton JR, Kelly KA, Mahmood U, Weissleder R, and Deutscher S (2006). *In vivo* selection of phage for the optical imaging of human prostate carcinoma in mice. *Neoplasia* **8**, 772–780.
- [84] Wang Q, Zhou Y, and Evers B (2006). Neurotensin phosphorylates GSK-3 α/β through activation of PKC in human colon cancer cells. *Neoplasia* **8**, 781–787.
- [85] Lammers T, Peschke P, Kühnlein R, Subr V, Ulbrich K, Huber P, Hennink W, and Storm G (2006). Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. *Neoplasia* **8**, 788–795.
- [86] Winnard PT Jr, Kluth J, and Raman V (2006). Non-invasive optical tracking of red fluorescent protein expressing cancer cells in a model of metastatic breast cancer. *Neoplasia* **8**, 796–806.
- [87] Blaheta R, Weich E, Marian D, Bereiter-Hahn J, Jones J, Jonas D, Michaelis M, Doerr HW, and Cinat J (2006). Human cytomegalovirus infection alters PC3 prostate carcinoma cell adhesion to endothelial cells and extracellular matrix. *Neoplasia* **8**, 807–816.
- [88] Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, Kijima T, Kumagai T, Yoshida M, Tachibana I, et al. (2006). Overexpression of P1AS3 suppresses cell growth and restores drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. *Neoplasia* **8**, 817–825.
- [89] Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, Jeronimo C, and Teixeira MR (2006). *TMPS22-ERG* gene fusion causing *ERG* overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. *Neoplasia* **8**, 826–832.
- [90] Morandi F, Chiesa S, Bocca P, Millo E, Salis A, Solari M, Pistoia V, and Prigione I (2006). Tumor mRNA transfected dendritic cells stimulate generation of CTL that recognize neuroblastoma associated antigens and kill tumor cells: immunotherapeutic implications. *Neoplasia* **8**, 833–842.
- [91] Lee O, Hong S, Razvi MH, Dun Fa P, Powell SM, Smolkin M, Moskaluk CA, and El-Rifai W (2006). Expression of calcium binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas. *Neoplasia* **8**, 843–850.
- [92] Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM, and Catapano CV (2006). Cellular and molecular consequences of peroxisome proliferator-activated receptor- γ activation in ovarian cancer cells. *Neoplasia* **8**, 851–861.
- [93] Coleman IM, Kiefer JA, Brown LG, Pitts TE, Nelson P, Brubaker KD, Vessella RL, and Corey E (2006). Inhibition of androgen-independent prostate cancer by estrogenic compounds is associated with the increased expression of immune-related genes. *Neoplasia* **8**, 862–878.
- [94] Ben-Izhak O, Kaplan-Cohen V, Ilan N, Gan S, Vlodavsk I, and Nagler RM (2006). Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. *Neoplasia* **8**, 879–884.
- [95] Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, and Chinnaiyan AM (2006). Noninvasive detection of *TMPS22:ERG* fusion transcripts in the urine of men with prostate cancer. *Neoplasia* **8**, 885–888.
- [96] Pore N, Gupta AK, Cerniglia GJ, and Maity A (2006). HIV protease inhibitors decrease VEGF/HIF-1 α expression and angiogenesis in glioblastoma cells. *Neoplasia* **8**, 889–895.
- [97] Mak P, Leung Y, Tang W, Harwood CM, and Ho S (2006). Apigenin suppresses cancer cell growth via ER β . *Neoplasia* **8**, 896–904.
- [98] Wellman A, Cawthorne C, Ponce-Perez L, Barraclough J, Danson S, Murray S, Cummings J, Allen TD, and Dive C (2006). Increases in c-Src expression level and activity do not promote growth of human colorectal carcinoma cells *in vitro* and *in vivo*. *Neoplasia* **8**, 905–916.
- [99] Liu L, Zhang Q, Zhang Y, Wang S, and Ding Y (2006). Lentivirus-mediated silencing of *Tiam1* gene influences multiple functions of human colorectal cancer cell line. *Neoplasia* **8**, 917–924.
- [100] Zhou X, Temam S, Oh M, Pungpravat N, Huang B, Mao L, and Wong DT (2006). Global expression based classification of lymph node metastasis and extracapsular spread of oral tongue squamous cell carcinoma. *Neoplasia* **8**, 925–932.
- [101] Diegmann J, Junker K, Loncarevic IF, Michel S, Schimmel B, and von Eggeling F (2006). Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. *Neoplasia* **8**, 933–938.
- [102] Heimburg J, Yan J, Morey SM, Glinskii OV, Huxley VH, Wild L, Klick R, Roy R, Glinsky V, and Rittenhouse-Olson K (2006). Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11. *Neoplasia* **8**, 939–948.
- [103] Watson GA, Zhang X, Stang MT, Levy RM, Queiroz de Oliveira PE, Gooding WE, Christensen JG, and Hughes SJ (2006). Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. *Neoplasia* **8**, 949–955.
- [104] Sufan RI and Ohh M (2006). Role of NEDD8 modification of Cul2 in sequential activation of the ECV complex. *Neoplasia* **8**, 956–963.
- [105] Armstrong MB, Bian X, Liu Y, Subramanian C, Ratanaproeaksa AB, Shao F, Yu VC, Kwok R, Opipari AW Jr, and Castle VP (2006). Signaling from p53 to NF- κ B determines chemotherapy responsiveness of neuroblastoma. *Neoplasia* **8**, 964–977.
- [106] Aravindakshan J, Chen X, and Sairam M (2006). Differential expression of claudin family proteins in mouse ovarian serous papillary epithelial adenoma in aging FSH receptor deficient mutants. *Neoplasia* **8**, 984–994.
- [107] Song J, Xie H, Lian Z, Yang G, Du R, Du Y, Zou X, Jin H, Gao J, Liu J, et al. (2006). Enhanced cell survival of gastric cancer cells by a novel gene *URG4*. *Neoplasia* **8**, 995–1002.
- [108] Takahashi M, Yoshimoto T, Shimoda M, Kono T, Koizumi M, Yazumi S, Shimada Y, Doi R, Chiba T, and Kubo H (2006). Loss of function of the candidate tumor suppressor *prox1* by RNA mutation in human cancer cells. *Neoplasia* **8**, 1003–1010.
- [109] Kelly KA, Waterman P, and Weissleder R (2006). *In vivo* imaging of molecularly targeted phage. *Neoplasia* **8**, 1011–1018.
- [110] Fink C, Weigel R, Hembes T, Lauke-Wettwer H, Kliesch S, Bergmann M, and Brehm R (2006). Altered expression of ZO-1 and -2 in Sertoli cells and loss of the blood-testis barrier integrity in testicular carcinoma-*in-situ*. *Neoplasia* **8**, 1019–1027.
- [111] Peng H, Shintani S, Kim Y, and Wong DT (2006). Loss of p12^{CDK2-AP1} expression in human oral squamous cell carcinoma with disrupted transforming growth factor-Smad signaling pathway. *Neoplasia* **8**, 1028–1036.
- [112] Pajonk F, Grumann TF, and McBride WH (2006). The proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiation. *Neoplasia* **8**, 1037–1041.

- [113] Tan M, Gallegos JR, Gu Q, Huang Y, Li J, Jin Y, Lu H, and Sun Y (2006). SAG/ROC-SCF^{β-TCP} E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection. *Neoplasia* **8**, 1042–1054.
- [114] Doweck I, Kaplan V, Naroditsky I, Sabo E, Ilan N, and Vlodavsky I (2006). Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient's survival. *Neoplasia* **8**, 1055–1061.
- [115] Lin J, Raoof DA, Wang Z, Lin M, Thomas DG, Greenon JK, Giordano TJ, Orringer MB, Chang AC, Beer DG, et al. (2006). Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C in esophageal adenocarcinoma. *Neoplasia* **8**, 1062–1071.
- [116] Shih A and Holland EC (2006). Notch signaling enhances nestin expression in gliomas. *Neoplasia* **8**, 1072–1082.
- [117] Paris P, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridlyand J, Simko J, Carroll PR, Rubin MA, et al. (2006). Genomic profiling of hormone naïve lymph node metastases in patients with prostate cancer. *Neoplasia* **8**, 1083–1089.
- [118] Zhao C, Annamalai L, Guo C, Narasimhan K, Koh S, Zhang H, Biswas A, and Choolani M (2007). Circulating haptoglobin is an independent prognostic factor in sera of patients with epithelial ovarian cancer. *Neoplasia* **9**, 1–7.
- [119] Esposito I, Kaye H, Keleg S, Giese T, Sage H, Schirmacher P, Friess H, and Kleeff J (2007). Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. *Neoplasia* **9**, 8–17.
- [120] Uhm J, Lim H, Kim W, Choi H, Lee H, Park B, Park K, and Kang W (2007). Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of urothelial tract. *Neoplasia* **9**, 18–22.
- [121] Said NA, Najwer I, Socha MJ, Fulton DJ, Mok S, and Motamed K (2007). SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. *Neoplasia* **9**, 23–35.
- [122] Zhang L, Yeager H, Das B, Irwin MS, and Baruchel S (2007). Tissue micro-environment modulates CXCR4 expression and tumor metastasis in neuroblastoma. *Neoplasia* **9**, 36–46.
- [123] Telang S, Clem AL, Eaton JW, and Chesney J (2007). Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. *Neoplasia* **9**, 47–56.
- [124] Zechmann CM, Woenne EC, Brix G, Radzwill N, Ilg M, Bachert P, Peschke P, Kirsch S, Kauczor H, Delorme S, et al. (2007). Impact of stroma on growth, microcirculation and metabolism of experimental prostate tumors. *Neoplasia* **9**, 57–67.
- [125] Pinthus JH, Bryskin I, Trachtenberg J, Lu J, Singh G, Fridman E, and Wilson BC (2007). Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. *Neoplasia* **9**, 68–80.
- [126] Joshua A, Vukovic B, Braude I, Hussein S, Zielenska M, Srigley J, Evans AJ, and Squire JA (2007). Telomere attrition of isolated high-grade prostatic intra-epithelial neoplasia and surrounding stroma is predictive of prostate cancer. *Neoplasia* **9**, 81–90.
- [127] Chang Y, Kung H, and Evans CP (2007). Non-receptor tyrosine kinases in prostate cancer. *Neoplasia* **9**, 90–100.
- [128] Agarwal SK, Impey S, McWeeney S, Scacheri PC, Collins FS, Goodman RH, Spiegel AM, and Marx SJ (2007). Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. *Neoplasia* **9**, 101–107.
- [129] Ley CD, Horsman MR, and Kristjansen P (2007). Early effects of combretastatin A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. *Neoplasia* **9**, 108–112.
- [130] Bandyopadhyay A, Wang L, Chin S, and Sun L (2007). Inhibition of skeletal metastasis by ectopic ERα expression in ERα negative human breast cancer cell lines. *Neoplasia* **9**, 113–118.
- [131] Buechler P, Reber HA, Roth MM, Shiroishi M, Friess H, and Hines OJ (2007). Target therapy using a small molecular inhibitor against angiogenic receptors in pancreatic cancer. *Neoplasia* **9**, 119–127.
- [132] Seshadri M, Sperryak J, Maier P, Cheney RT, Mazurchuk R, and Bellnier DA (2007). Visualizing the acute effects of vascular-targeted therapy *in vivo* using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction and treatment outcome. *Neoplasia* **9**, 128–135.
- [133] Jesenofsky R, Zoubakov D, Faissner R, Ringel J, Hoheisel JD, Lösel R, Schnözer M, and Löhr M (2007). Genes and proteins differentially expressed during *in vitro* malignant transformation of bovine pancreatic duct cells. *Neoplasia* **9**, 136–146.
- [134] Azios NG, Krishnamoorthy L, Harris M, Cubano L, Cammer M, and Dharmawardhane SF (2007). Estrogen and resveratrol regulate Rac and Cdc42 signaling to the actin cytoskeleton of metastatic breast cancer cells. *Neoplasia* **9**, 147–158.
- [135] Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, Takeda A, Siffert W, Schmid KW, and Baba HA (2007). The *GNAS1* T393C polymorphism is associated with the clinical course in patients with intrahepatic cholangiocarcinoma. *Neoplasia* **9**, 159–165.
- [136] Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs B, Barrette T, Anstett MJ, Kincaid-Beal C, Kulkarni P, et al. (2007). Oncomine 3.0: genes, pathways and networks in a collection of 18,000+ cancer gene expression profiles. *Neoplasia* **9**, 166–180.
- [137] Dalai I, Missiaglia E, Barbi S, Butturini G, Doglioni C, Falconi M, and Scarpa A (2007). Low expression of ARHI is associated with shorter progression-free survival in pancreatic endocrine tumours. *Neoplasia* **9**, 181–183.
- [138] Qiao J, Kang J, Cree J, Evers B, and Chung DH (2007). ETS1 transcription factor mediates gastrin releasing peptide-induced IL-8 regulation in neuroblastoma cells. *Neoplasia* **9**, 184–191.
- [139] Schepher MA, Nikitakis N, Chaisuparat R, Montaner S, and Sauk JJ (2007). Sulindac induces apoptosis and inhibits tumor growth *in vivo* in head and neck squamous cell carcinoma. *Neoplasia* **9**, 192–199.
- [140] Mertz KD, Setlur SR, Dhanasekaran SM, Demicheli F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhi R, et al. (2007). Molecular characterization of the *TMPRSS2-ERG* gene fusion in the NCI-H660 prostate cancer cell line—a new perspective for an old model. *Neoplasia* **9**, 200–206.
- [141] Yi Y, Grubbs CJ, Lubet RA, and You M (2007). Gene expression profiling of chemically induced rat bladder tumors. *Neoplasia* **9**, 207–221.
- [142] Ackerstaff E, Gimi B, Artemov D, and Bhujwala ZM (2007). Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. *Neoplasia* **9**, 222–235.
- [143] Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F, Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A, et al. (2007). Early involvement of death-associated protein kinase promoter hypermethylation in the carcinogenesis of Barrett's esophageal adenocarcinoma and its association with clinical progression. *Neoplasia* **9**, 236–245.
- [144] Kuefer R, Genze F, Zugmaier W, Hautmann RE, Rinnab L, Gschwend JE, Angelmeier M, Estrada A, and Bueschle B (2007). Antagonistic effects of sodium butyrate and *N*-(4-hydroxyphenyl)-retinamide on prostate cancer. *Neoplasia* **9**, 246–253.
- [145] Escher N, Kaatz M, Melle C, Hippler U, Ziemer M, Driesch D, Wollina U, and von Eggeling F (2007). Post-translational modifications of transthyretin are serum markers in patients with mycosis fungoides. *Neoplasia* **9**, 254–259.
- [146] Akizuki M, Fukutomi T, Takasugi M, Takahashi S, Sato T, Harao M, Mizumoto T, and Yamashita J (2007). Prognostic significance of immunoreactive neutrophil elastase in human breast cancer: long-term follow-up results in three hundred and thirteen patients. *Neoplasia* **9**, 260–265.
- [147] Rashid-Kolvear F, Pintilie M, and Done SJ (2007). Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer. *Neoplasia* **9**, 265–270.
- [148] Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, and Maity A (2007). The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. *Neoplasia* **9**, 271–278.
- [149] Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Schütz A, Kovacic B, and Friedrich K (2007). Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. *Neoplasia* **9**, 279–291.
- [150] Yu J, Almal AA, Dhanasekaran SM, Ghosh D, Worzel WP, and Chinnaiyan AM (2007). Feature selection and molecular classification of cancer using genetic programming. *Neoplasia* **9**, 292–303.
- [151] Litkouhi B, Kwong J, Lo C, Smedley JG, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, et al. (2007). Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of *Clostridium perfringens* enterotoxin. *Neoplasia* **9**, 304–314.
- [152] Cheng Y, Zhang Z, Slape C, and Aplan PD (2007). Cre-loxP mediated recombination between the *SIL* and *SCL* genes leads to a block in T-cell development at the CD4⁺CD8⁺ to CD4⁺CD8⁺ transition. *Neoplasia* **9**, 315–321.
- [153] Vandyke K, White MY, Nguyen-Khuong T, Ow K, Luk S, Kingsley EA, Rowe A, Pang S, Walsh BJ, and Russell PJ (2007). Plant derived MINA-05 inhibits human prostate cancer proliferation *in vitro* and lymph node spread *in vivo*. *Neoplasia* **9**, 322–331.

- [154] Belkaid A, Fortier S, Cao J, and Annabi B (2007). Necrosis induction in glioblastoma cells reveals a new "bio-switch" function for the MT1-MMP/G6PT signalling axis in proMMP-2 activation *versus* death cell decision. *Neoplasia* **9**, 332–340.
- [155] Cengel KA, Voong K, Chandrasekaran S, Maggiorella L, Brunner TB, Stanbridge E, Kao GD, McKenna W, and Bernhard EJ (2007). Oncogenic K-Ras signals through EGFR and wild type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. *Neoplasia* **9**, 341–348.
- [156] Millimaggi D, Mari M, D'Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, and Dolo V (2007). Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. *Neoplasia* **9**, 349–357.
- [157] Veronique MM, Mathieu V, Mijatovic T, Gailly P, Debeir O, De Nève N, Van Damme M, Decaestecker C, Kondo Y, Kiss R, et al. (2007). 4-IBP: a $\sigma 1$ receptor agonist decreases the migration of human cancer cells including glioblastoma cells *in vitro* and sensitizes them *in vitro* and *in vivo* to the cytotoxic insults of pro-apoptotic and pro-autophagic drugs. *Neoplasia* **9**, 358–369.
- [158] Ali M, Choy H, Habib AA, and Saha D (2007). SNS-032 prevents tumor cell induced angiogenesis by inhibiting vascular endothelial growth factor. *Neoplasia* **9**, 370–381.
- [159] Bradley DP, Tessier JJ, Ashton SE, Waterton JC, Wilson Z, Worthington PL, and Ryan AJ (2007). Correlation of MRI biomarkers with tumour necrosis in Hras5 tumour xenograft in athymic rats. *Neoplasia* **9**, 382–391.
- [160] Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, and Olsen D (2007). Early changes in apparent diffusion coefficient predict the quantitative anti-tumoral activity of capecitabine, oxaliplatin and irradiation in HT29 xenografts in athymic nude mice. *Neoplasia* **9**, 392–400.
- [161] You M, Yan Y, Cook J, McQuillan J, Zhang G, Hitzman C, Wang Y, and Wiedmann T (2007). Chemopreventive effect of aerosolized polyphenol E against lung tumorigenesis in A/J mice. *Neoplasia* **9**, 401–405.
- [162] Sroka IC, Nagle RB, and Bowden TG (2007). Membrane-type 1 matrix metallo-proteinase is regulated by Sp1 through differential activation of AKT, JNK and ERK pathways in human prostate tumor cells. *Neoplasia* **9**, 406–417.
- [163] Liu D and Hornsby P (2007). Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase the effect. *Neoplasia* **9**, 418–426.
- [164] Alimirah F, Panchanathan R, Davis FJ, Chen J, and Choubey D (2007). Restoration of p53 expression in human cancer cell lines up-regulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. *Neoplasia* **9**, 427–434.
- [165] Kock N, Kasmieh R, Weissleder R, and Shah K (2007). Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. *Neoplasia* **9**, 435–442.
- [166] Rhodes DR, Kalyana-Sundaram S, Tomlins SA, Mahavisno V, Kasper N, Varambally R, Barrette TR, Varambally S, and Chinnaiyan AM (2007). Molecular concepts analysis links tumors, pathways, mechanisms and drugs. *Neoplasia* **9**, 443–454.
- [167] Zapotoczna A, Sasso G, Simpson J, and Roach M (2007). Current role and future perspectives of MR spectroscopy in radiation oncology for prostate cancer. *Neoplasia* **9**, 455–463.
- [168] You Z, Dong Y, Kong X, Zhang Y, Vessella RL, and Melamed J (2007). Differential expression of IL-17RC isoforms in androgen-dependent and androgen-independent prostate cancer. *Neoplasia* **9**, 464–470.
- [169] Yanglin P, Zhao L, Zhai H, Li X, He L, Sun L, Chen Y, Hong L, Du Y, and Fan D (2007). p75 neurotrophin receptor suppresses proliferation of human gastric cancer cells. *Neoplasia* **9**, 471–478.
- [170] Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, and Klostergaard J (2007). Hyaluronic acid–paclitaxel: anti-tumor efficacy against CD44(+) human ovarian carcinoma xenografts. *Neoplasia* **9**, 479–486.
- [171] Halpern M, Zahalka MA, Traub L, and Moroz C (2007). Antibodies to placental immunoregulatory ferritin (PLIF) with transfer of polyclonal lymphocytes arrests MCF-7 human breast cancer growth in nude mouse model. *Neoplasia* **9**, 487–494.
- [172] Subramaniam C, Jarzembowski JA, Opiari AW Jr, Castle VP, and Kwok P (2007). Creb-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor, trichostatin A. *Neoplasia* **9**, 495–503.
- [173] Theodoro TR, Luango de Matos L, Sant Anna AV, Fonseca FL, Smedo P, Martins LC, Nader HB, Del Giglio A, and Pinhal MS (2007). Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. *Neoplasia* **9**, 504–510.
- [174] Ghazani A, Arneson N, Warren K, Pintilie M, Bayani J, Squire JA, and Done SJ (2007). Genomic alterations in sporadic synchronous primary breast cancer using array and metaphase comparative genomic hybridization. *Neoplasia* **9**, 511–520.
- [175] Chen X, Aravindakshan J, Yang Y, and Sairam MR (2007). Early alterations in ovarian surface epithelial cells and induction of ovarian epithelial tumors triggered by loss of FSH receptor. *Neoplasia* **9**, 521–531.
- [176] Lindberg D, Åkerström G, and Westin G (2007). Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor suppressor function. *Neoplasia* **9**, 533–535.
- [177] Derouet M, Wu X, May L, Yoo BH, Sasazuki T, Shirasawa S, Rak J, and Rosen K (2007). Acquisition of anoikis resistance promotes the emergence of oncogenic K-ras mutations in colorectal cancer cells and stimulates their tumorigenicity *in vivo*. *Neoplasia* **9**, 536–545.
- [178] Ferrier MC, Sarin H, Fung SH, Schatlo B, Pluta RM, Gupta SN, Choyke PL, Oldfield EH, Thomasson D, and Butman JA (2007). Validation of dynamic contrast enhanced magnetic resonance imaging–derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. *Neoplasia* **9**, 546–555.
- [179] Loberg RD, Ying C, Craig MJ, Yan L, Snyder L, and Pienta KJ (2007). CCL2 is an important mediator of prostate cancer growth *in vivo* via regulation of macrophage infiltration. *Neoplasia* **9**, 556–562.
- [180] Wade T and Kozlowski P (2007). Longitudinal studies of angiogenesis in hormone dependent Shionogi tumors. *Neoplasia* **9**, 563–568.
- [181] Kawasaki T, Noshio K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS, and Ogino S (2007). Correlation of β -catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer. *Neoplasia* **9**, 569–577.
- [182] Guffei A, Lichtensztejn Z, Silva AG, Louis SF, Caporali A, and Mai S (2007). c-Myc–dependent formation of robertsonian translocation chromosomes in mouse cells. *Neoplasia* **9**, 578–588.
- [183] Lovvorn HN III, Westrup J, Opperman S, Boyle SC, Shi G, Anderson J, Perlman EJ, Perantoni AO, Wills M, and de Caestecker M (2007). CITED1 expression in Wilms' tumor and embryonic kidney. *Neoplasia* **9**, 589–600.
- [184] Tedesco D, Zhang J, Trinh L, Lalehzadeh G, Meisner R, Yamaguchi KD, Ruderman DL, Dinter H, and Zajchowski D (2007). The ubiquitin-conjugating enzyme E2-EPF is over-expressed in primary breast cancer and modulates sensitivity to Topoisomerase II inhibition. *Neoplasia* **9**, 601–613.
- [185] Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubrea F, Cortes M, Ropero S, Colomer R, Lopez Ruiz PM, and Colas B (2007). EGF prevents neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K-Akt. *Neoplasia* **9**, 614–624.
- [186] Ammons S, Wang J, Yang Z, Tidmarsh GF, and Hoffman RM (2007). A novel alkylating agent, glufosamide, enhances activity of gemcitabine *in vitro* and *in vivo*. *Neoplasia* **9**, 625–633.
- [187] Choi EK, Terai K, Ji I, Kook YH, Park KH, Oh E, Griffin RJ, Lim BU, Kim J, Lee DS, et al. (2007). Upregulation of NAD(P)H:quinone oxidoreductase (NQO1) by radiation potentiates the effect of bioreductive β -lapachone against cancer cells. *Neoplasia* **9**, 634–642.
- [188] Oram SW, Ai J, Pagani GM, Hitchens MR, Stern JA, Eggner S, Pins M, Xiao W, Cai X, Haleem R, et al. (2007). Expression and function of the human androgen-responsive gene ADII in prostate cancer. *Neoplasia* **9**, 643–651.
- [189] Zhang G, Chen T, Bednar B, Connolly B, Hargreaves R, Sur C, and Williams DL Jr (2007). Optical imaging of tumor cells in hollow fibers; evaluation of anti-tumor activities of anti-cancer drugs and target validation. *Neoplasia* **9**, 652–661.
- [190] Johnson KD, Glinkii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinkin GV, Pienta KJ, et al. (2007). Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelium. *Neoplasia* **9**, 662–670.
- [191] Holtkamp N, Atallah I, Okuducu A, Mucha J, Hartmann C, Mautner VF, Friedrich RE, Mawrin C, and von Deimling A (2007). MMP-13 and p53 in progression of malignant peripheral nerve sheath tumors. *Neoplasia* **9**, 671–677.
- [192] Entz-Werle N, Lavaux T, Metzger N, Stoelzel C, Lasthaus C, Marec-Berard P, Kalifa C, Brugieres L, Pacquement H, Schmitt C, et al. (2007). Involvement of the MET/TWIST/APC combination or the potential role of ossification factors in pediatric high grade osteosarcoma oncogenesis. *Neoplasia* **9**, 678–688.
- [193] Kast RE (2007). Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists. *Neoplasia* **9**, 689.

- [194] Lee M and Sabapathy K (2007). Phosphorylation at the carboxyl terminal S373 and S375 residues and 14-3-3 binding are not required for mouse p53 function. *Neoplasia* **9**, 690–698.
- [195] Gao C, Mi Z, Guo H, and Kuo PC (2007). Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells. *Neoplasia* **9**, 698–706.
- [196] Matarasso N, Bar-Shira A, Rozovsky U, Rosner S, and Orr-Urtreger A (2007). Functional analysis of the aurora kinase A Ile31 allelic variant in the human prostate. *Neoplasia* **9**, 707–715.
- [197] Röcken C, Neumann K, Carl-McGrath S, Lage H, Ebert MP, Dierkes J, Jacobi CA, Kalmuk S, Neuhaus P, and Neumann U (2007). The gene polymorphism of the angiotensin I-converting enzyme correlates with tumor size and patient survival in colorectal cancer patients. *Neoplasia* **9**, 716–722.
- [198] Guimaraes-Ferreira CA, Rodrigues EG, Mortara RA, Cabral H, Serrano F, Ribeir-dos-Santos R, and Travassos LR (2007). Anti-tumor effects *in vitro* and *in vivo* and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosin, a cysteine proteinase from *Bromelia fastuosa*. *Neoplasia* **9**, 723–733.
- [199] Mita R, Coles J, Glubrecht DD, Sung R, Sun X, and Godbout R (2007). B-FABP-expressing radial glial cells—the malignant glioma cell-of-origin? *Neoplasia* **9**, 734–744.
- [200] Barraclough J, Hodgkinson C, Hogg A, Dive C, and Welman A (2007). Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. *Neoplasia* **9**, 745–754.
- [201] Missbach-Guentner J, Dullin C, Zientkowska M, Domeyer-Missbach M, Kimmina S, Obenauer S, Kauer F, Stühmer W, Grabbe E, Vogel WF, et al. (2007). Flat-panel detector based volume computed tomography: a novel 3D imaging technique to monitor osteolytic bone lesions in a mouse tumor metastasis model. *Neoplasia* **9**, 755–765.
- [202] Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F, and Kiss R (2007). The amaryllidaceae isocarbostyryl narciclasine induces apoptosis by activation of the death receptor and/or the mitochondrial pathways in cancer cells but not in normal fibroblasts. *Neoplasia* **9**, 766–776.
- [203] Hayashi Y, Edwards NA, Proescholdt MA, Oldfield EH, and Merrill MJ (2007). Regulation and function of aquaporin-1 in glioma cells. *Neoplasia* **9**, 777–787.
- [204] Turcotte S, Forget M, Beauseigle D, Nassif E, and Lapointe R (2007). Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer. *Neoplasia* **9**, 788–796.
- [205] Winter SL, Bosnyan-Collins L, Pinnaduwa D, and Andrulis IL (2007). Expression of the circadian clock genes *Per1* and *2* in sporadic and familial breast tumors. *Neoplasia* **9**, 797–800.
- [206] Li R, Boehm AL, Miranda MB, Shangary S, Grandis JR, and Johnson DE (2007). Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. *Neoplasia* **9**, 801–811.
- [207] Shen W, Wu J, Cai L, Liu B, Gao Y, Chen G, and Fu G (2007). Expression of anion exchanger 1 sequesters p16 in cytoplasm in gastric and colonic adenocarcinoma. *Neoplasia* **9**, 812–819.
- [208] Puiffe M, Le Page C, Filali-Mouhim A, Ziertarska M, Ouellet V, Tonin PN, Chevrete M, Provencher DM, and Mes-Masson A (2007). Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation and gene expression in an *in vitro* model of epithelial ovarian cancer. *Neoplasia* **9**, 820–829.
- [209] Lin S, Chueh S, Hsiao C, Li T, Chen T, Liao C, Lyu P, and Guh JH (2007). Prazosin displays anticancer activity against human prostate cancers—targeting on DNA and cell cycle. *Neoplasia* **9**, 830–839.
- [210] Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-De-Solorzano C, Pio R, Lecanda F, et al. (2007). Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. *Neoplasia* **9**, 840–852.
- [211] Secchiero P, Zerbinati C, Melloni E, Milani D, Campioni D, Fadda R, Tiribelli M, and Zauli G (2007). The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. *Neoplasia* **9**, 853–861.
- [212] Kollmar O, Rupertus K, Scheuer C, Junker B, Tilton B, Schilling MK, and Menger MD (2007). Stromal cell-derived factor (SDF)-1 promotes cell migration and tumor growth of colorectal metastasis. *Neoplasia* **9**, 862–870.
- [213] Mei Y and Wu M (2007). Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis. *Neoplasia* **9**, 871–881.
- [214] Sakariassen PØ, Immervoll H, and Chekenya M (2007). Cancer stem cells as mediators of treatment resistance in brain tumours: status and controversies. *Neoplasia* **9**, 882–892.
- [215] Ghosh R, Garcia GE, Crosby K, Inoue H, Thompson IM, Troyer DA, and Kumar A (2007). Regulation of Cox-2 by cyclic-AMP response element binding protein (CREB) in prostate cancer: potential role for NexrutineR. *Neoplasia* **9**, 893–899.
- [216] Galìè M, Farace P, Nanni C, Spinelli A, Nicolato E, Boschi F, Magnani P, Trespidi S, Ambrosini V, Fanti S, et al. (2007). Epithelial and mesenchymal tumor compartments exhibit *in vivo* complementary patterns of vascular perfusion and glucose metabolism. *Neoplasia* **9**, 900–908.
- [217] Shafat I, Ben Barak A, Postovsky S, Elhasid R, Vlodavsky I, Vlodavsky I, and Ben Arush M (2007). Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anti-cancer treatment. *Neoplasia* **9**, 909–916.
- [218] Hennig R, Kehl T, Noor S, Ding X, Rao SM, Bergmann F, Furstenberger G, Buchler MW, Friess H, Krieg P, et al. (2007). 15-Lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. *Neoplasia* **9**, 917–926.
- [219] Devy L, Rabbani SA, Stochl M, Ruskowski M, Mackie I, Naa L, Toews M, van Gool R, Chen J, Ley A, et al. (2007). PEGylated DX-1000: pharmacokinetics and anti-neoplastic activity of a specific plasmin inhibitor. *Neoplasia* **9**, 927–937.
- [220] Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, and Smith GJ (2007). Origin of androgen insensitive poorly-differentiated tumors in the transgenic adenocarcinoma of mouse prostate model (TRAMP). *Neoplasia* **9**, 938–950.
- [221] Zeng G, Apte U, Cieply B, Singh S, and Monga SS (2007). siRNA-mediated β -catenin knockdown in human hepatoma cells results in decreased growth and survival. *Neoplasia* **9**, 951–959.
- [222] Cerruti F, Martano M, Petterino C, Bollo E, Morello E, Bruno R, Buracco P, and Cascio P (2007). Enhanced expression of interferon- γ -induced antigen processing machinery components in a spontaneously occurring cancer. *Neoplasia* **9**, 960–969.
- [223] Chilukamarri L, Hancock AL, Malik S, Zabkiewicz J, Baker JA, Dallosso AR, Huang TH, Royor-Pokora B, Brown KW, and Malik K (2007). Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms' tumours. *Neoplasia* **9**, 970–978.
- [224] Nakamura T, Kuwai T, Kim J, Fan D, Kim S, and Fidler IJ (2007). Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. *Neoplasia* **9**, 979–986.
- [225] Jeng J, Tsai J, Chuang L, Ho M, Lin Z, Hsieh M, Chen S, Chuang W, Wang L, Yu M, et al. (2007). Tumor necrosis factor- α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. *Neoplasia* **9**, 987–992.
- [226] Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, et al. (2007). A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. *Neoplasia* **9**, 1003–1011.
- [227] Maratheftis CI, Giannouli S, Spachidou MP, Panayotou G, and Voulgarelis M (2007). RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II. *Neoplasia* **9**, 1012–1020.
- [228] Koyama Y, Barrett T, Hama Y, Ravizzini G, Choyke PL, and Kobayashi H (2007). *In vivo* molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies. *Neoplasia* **9**, 1021–1029.
- [229] Loberg RD, McGregor N, Ying C, Sargent E, and Pienta KJ (2007). *In vivo* evaluation of AT-101 (*R*-(–)-gossypol acetic acid) in androgen independent growth of VCaP prostate cancer cells in combination with surgical castration. *Neoplasia* **9**, 1030–1037.
- [230] Nelson GM, Padera TP, Gakavtsev I, Shioda T, and Jain RK (2007). Differential gene expression of primary cultured lymphatic and blood vascular endothelial cells. *Neoplasia* **9**, 1038–1045.
- [231] Crich SG, Lanzardo S, Alberti D, Belfiore S, Ciampa A, Giovanzana GB, Lovazzano C, Pagliarin R, and Aime S (2007). MRI detection of tumor cells by targeting LDL receptors with Gd-loaded LDL particles. *Neoplasia* **9**, 1046–1056.
- [232] Smith JM, Stubbert LJ, Hamill JD, and McKay BC (2007). The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific. *Neoplasia* **9**, 1057–1065.

- [233] Sasaki T, Kitadai Y, Nakamura T, Kim J, Tsan RZ, Kuwai T, Langley RR, Fan D, Kim S, and Fidler IJ (2007). Inhibition of EGFR and VEGFR phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice. *Neoplasia* **9**, 1066–1077.
- [234] Sarraibarrouse G, Synaeve C, Leveque K, Favre G, and Tilkin-Mariamé AF (2007). Statins stimulate *in vitro* membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. *Neoplasia* **9**, 1078–1090.
- [235] Kawasaki T, Noshio K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, and Ogino S (2007). IGF1BP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype (CIMP) and p53. *Neoplasia* **9**, 1091–1098.
- [236] Perera RM, Zoncu R, Johns TG, Pypaert M, Lee F, Mellman I, Old LJ, Toomre DK, and Scott AM (2007). Internalization, intracellular trafficking and biodistribution of monoclonal antibody 806: a novel anti-EGFR antibody. *Neoplasia* **9**, 1099–1110.
- [237] Campos AC, Molognoni F, Melo FH, Galdieri LC, Carneiro CR, D'Almeida V, Correa M, and Jasulionis MG (2007). Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. *Neoplasia* **9**, 1111–1121.
- [238] Phillips TM, Kim K, Vlasi E, McBride WH, and Pajonk F (2007). Effects of recombinant erythropoietin on breast cancer initiating cells. *Neoplasia* **9**, 1122–1129.
- [239] Pham W, Xie J, and Gore J (2007). Tracking the migration of dendritic cells by *in vivo* optical imaging. *Neoplasia* **9**, 1130–1137.
- [240] Ackerstaff E, Artemov D, Gillies RJ, and Bhujwala ZM (2007). Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism. *Neoplasia* **9**, 1138–1151.
- [241] Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, and Choubey D (2007). Expression of androgen receptor is negatively regulated by p53. *Neoplasia* **9**, 1152–1159.
- [242] Harisinghani M, Ross R, Guimaraes A, and Weissleder R (2007). Utility of a new bolus injectable nanoparticle for clinical cancer staging. *Neoplasia* **9**, 1160–1165.
- [243] Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, and Hartmann A (2008). Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. *Neoplasia* **10**, 1–7.
- [244] Crissey MA, Guo RJ, Fogt F, Li H, Katz JP, Silberg DG, Suh ER, and Lynch JP (2008). The homeodomain transcription factor Cdx1 does not behave as an oncogene in normal mouse intestine. *Neoplasia* **10**, 8–19.
- [245] Tam NN, Szeto CY, Sartor MA, Medvedovic M, and Ho SM (2008). Gene expression profiling identifies lobe-specific and common disruptions of multiple gene networks in testosterone-supported, 17 β -estradiol- or diethylstilbestrol-induced prostate dysplasia in Noble rats. *Neoplasia* **10**, 20–40.
- [246] Cai J, Niu X, Chen Y, Hu Q, Shi G, Wu H, Wang J, and Yi J (2008). Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. *Neoplasia* **10**, 41–51.
- [247] Yeh HH, Wu CH, Giri R, Kato K, Kohno K, Izumi H, Chou CY, Su WC, and Liu HS (2008). Oncogenic Ras-induced morphologic change is through MEK/ERK signaling pathway to downregulate Stat3 at a posttranslational level in NIH3T3 cells. *Neoplasia* **10**, 52–60.
- [248] Rodrigues EG, Dobroff AS, Cavarsan CF, Paschoalin T, Nimrichter L, Mortara RA, Santos EL, Fazio MA, Miranda A, Daffre S, et al. (2008). Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. *Neoplasia* **10**, 61–68.
- [249] Kim MK, Mason JM, Li CM, Berkofsky-Fessler W, Jiang L, Choubey D, Grundy PE, Tycko B, and Licht JD (2008). A pathologic link between Wilms tumor suppressor gene, *WT1*, and *IFI16*. *Neoplasia* **10**, 69–78.
- [250] Yu J, Yu J, Cordero KE, Johnson MD, Ghosh D, Rae JM, Chinnaiyan AM, and Lippman ME (2008). A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. *Neoplasia* **10**, 79–88.
- [251] De Smaele E, Fragomeli C, Ferretti E, Pelloni M, Po A, Canettieri G, Coni S, Di Marcotullio L, Greco A, Moretti M, et al. (2008). An integrated approach identifies *Nhlh1* and *Insm1* as Sonic Hedgehog-regulated genes in developing cerebellum and medulloblastoma. *Neoplasia* **10**, 89–98.
- [252] Vojtechova M, Tureckova J, Kucerova D, Sloncová E, Vachtenheim J, and Tuhackova Z (2008). Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells. *Neoplasia* **10**, 99–107.
- [253] Banciu M, Metselaar JM, Schifferers RM, and Storm G (2008). Antitumor activity of liposomal prednisolone phosphate depends on the presence of functional tumor-associated macrophages in tumor tissue. *Neoplasia* **10**, 108–117.
- [254] Huang S, Chen Y, Podsypanina K, and Li Y (2008). Comparison of expression profiles of metastatic *versus* primary mammary tumors in MMTV-Wnt-1 and MMTV-Neu transgenic mice. *Neoplasia* **10**, 118–124.
- [255] Shafat I, Pode D, Peretz T, Ilan N, Vlodavsky I, and Nisman B (2008). Clinical significance of urine heparanase in bladder cancer progression. *Neoplasia* **10**, 125–130.
- [256] Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, and Nor JE (2008). Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. *Neoplasia* **10**, 131–139.
- [257] Henkhaus RS, Roy UK, Cavallo-Medved D, Sloane BF, Gerner EW, and Ignatenko NA (2008). Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells. *Neoplasia* **10**, 140–148.
- [258] Hwang JH, Smith CA, Salhia B, and Rutka JT (2008). The role of fascin in the migration and invasiveness of malignant glioma cells. *Neoplasia* **10**, 149–159.
- [259] Yan M, Shen J, Person MD, Kuang X, Lynn WS, Atlas D, and Wong PK (2008). Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress. *Neoplasia* **10**, 160–167.
- [260] Rosenow F, Ossig R, Thormeyer D, Gasmann P, Schluter K, Brunner G, Haier J, and Eble JA (2008). Integrins as antimetastatic targets of RGD-independent snake venom components in liver metastasis [corrected]. *Neoplasia* **10**, 168–176.
- [261] Tomlins JR, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner SR, Rubin MA, Shah RB, et al. (2008). Role of the *TMPRSS2-ERG* gene fusion in prostate cancer. *Neoplasia* **10**, 177–188.
- [262] Lefranc F and Kiss R (2008). The sodium pump α_1 subunit as a potential target to combat apoptosis-resistant glioblastomas. *Neoplasia* **10**, 198–206.
- [263] Foster PJ, Dunn EA, Karl KE, Snir JA, Nycz CM, Harvey AJ, and Pettis RJ (2008). Cellular magnetic resonance imaging: *in vivo* imaging of melanoma cells in lymph nodes of mice. *Neoplasia* **10**, 207–216.
- [264] Craig DH, Downey C, and Basson MD (2008). siRNA-mediated reduction of α -actinin-1 inhibits pressure-induced murine tumor cell wound implantation and enhances tumor-free survival. *Neoplasia* **10**, 217–222.
- [265] Spankuch B, Steinhäuser I, Wärtlick H, Kurunci-Csacsko E, Strebhardt KI, and Langer K (2008). Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. *Neoplasia* **10**, 223–234.
- [266] Jiang W, Cazacu S, Xiang C, Zenklusen JC, Fine HA, Berens M, Armstrong B, Brodie C, and Mikkelsen T (2008). FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF- κ B signaling pathway. *Neoplasia* **10**, 235–243.
- [267] Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, and Macoska JA (2008). CXCL5 promotes prostate cancer progression. *Neoplasia* **10**, 244–254.
- [268] Sasaki M, Sakano S, Okayama N, Akao J, Hara T, Kawai Y, Ohmi C, Hinoda Y, and Naito K (2008). DNA repair gene polymorphisms may be associated with prognosis of upper urinary tract transitional cell carcinoma. *Neoplasia* **10**, 255–265.
- [269] Ateeq B, Unterberger A, Szyf M, and Rabbani SA (2008). Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes *in vitro* and *in vivo*. *Neoplasia* **10**, 266–278.
- [270] Menschikowski M, Hagelgans A, Gussakovsky E, Kostka H, Paley EL, and Siegert G (2008). Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. *Neoplasia* **10**, 279–286.
- [271] Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ, Lu R, Chen YX, and Fang JY (2008). Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. *Neoplasia* **10**, 287–297.
- [272] Perner S, Wagner PL, Demicheli F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ, et al. (2008). EML4-ALK fusion lung cancer: a rare acquired event. *Neoplasia* **10**, 298–302.
- [273] Chung YL, Troy H, Kristeleit R, Aherne W, Jackson LE, Atadja P, Griffiths JR, Judson IR, Workman P, Leach MO, et al. (2008). Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. *Neoplasia* **10**, 303–313.
- [274] Li Q, Mullins SR, Sloane BF, and Mattingly RR (2008). p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. *Neoplasia* **10**, 314–329.

- [275] Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, Lewis CE, and Hanahan D (2008). Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. *Neoplasia* **10**, 329–340.
- [276] van der Horst EH, Frank BT, Chinn L, Coxon A, Li S, Polesso F, Slavin A, Ruefli-Brasse A, and Wesche H (2008). The growth factor Midkine antagonizes VEGF signaling *in vitro* and *in vivo*. *Neoplasia* **10**, 340–347.
- [277] Gil Z, Kelly KJ, Brader P, Shah JP, Fong Y, and Wong RJ (2008). Utility of a herpes oncolytic virus for the detection of neural invasion by cancer. *Neoplasia* **10**, 347–353.
- [278] Gaustad JV, Brurberg KG, Simonsen TG, Mollatt CS, and Rofstad EK (2008). Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging. *Neoplasia* **10**, 354–362.
- [279] Coppola JM, Bhojani MS, Ross BD, and Rehemtulla A (2008). A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness. *Neoplasia* **10**, 363–370.
- [280] Havens AM, Pedersen EA, Shiozawa Y, Ying C, Jung Y, Sun Y, Neeley C, Wang J, Mehra R, Keller ET, et al. (2008). An *in vivo* mouse model for human prostate cancer metastasis. *Neoplasia* **10**, 371–380.
- [281] Mikhaylova M, Mori N, Wildes FB, Walczak P, Gimi B, and Bhujwala ZM (2008). Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. *Neoplasia* **10**, 380–389.
- [282] Li C, Greenwood TR, and Glunde K (2008). Glucosamine-bound near-infrared fluorescent probes with lysosomal specificity for breast tumor imaging. *Neoplasia* **10**, 389–398.
- [283] Wang S, Liu H, Ren L, Pan Y, and Zhang Y (2008). Inhibiting colorectal carcinoma growth and metastasis by blocking the expression of VEGF using RNA interference. *Neoplasia* **10**, 399–407.
- [284] Cruz-Monserrate Z and O'Connor KL (2008). Integrin $\alpha_6\beta_4$ promotes migration, invasion through Tiam1 upregulation, and subsequent Rac activation. *Neoplasia* **10**, 408–417.
- [285] Lorenzo PI and Saatcioglu F (2008). Inhibition of apoptosis in prostate cancer cells by androgens is mediated through downregulation of c-Jun N-terminal kinase activation. *Neoplasia* **10**, 418–428.
- [286] Mitra S and Foster TH (2008). *In vivo* confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. *Neoplasia* **10**, 429–438.
- [287] Dong Z, Saliganan AD, Meng H, Nabha SM, Sabbota AL, Sheng S, Bonfil RD, and Cher ML (2008). Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. *Neoplasia* **10**, 439–449.
- [288] Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, and Futscher BW (2008). Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. *Neoplasia* **10**, 450–461.
- [289] Sticht C, Freier K, Knopfle K, Flechtenmacher C, Pungs S, Hofele C, Hahn M, Joos S, and Lichter P (2008). Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). *Neoplasia* **10**, 462–470.
- [290] Al-Romaih K, Sadikovic B, Yoshimoto M, Wang Y, Zielenska M, and Squire JA (2008). Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. *Neoplasia* **10**, 471–480.
- [291] Giusti I, D'Ascenzo S, Millimaggi D, Taraboletti G, Carta G, Franceschini N, Pavan A, and Dolo V (2008). Cathepsin B mediates the pH-dependent pro-invasive activity of tumor-shed microvesicles. *Neoplasia* **10**, 481–488.
- [292] Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, Zigler M, Wang H, Bar-Eli M, Kerbel RS, et al. (2008). Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. *Neoplasia* **10**, 489–500.
- [293] Lyustikman Y, Momota H, Pao W, and Holland EC (2008). Constitutive activation of Raf-1 induces glioma formation in mice. *Neoplasia* **10**, 501–510.
- [294] Bauerle T, Hilbig H, Bartling S, Kiessling F, Kersten A, Schmitt-Graff A, Kauczor HU, Delorme S, and Berger MR (2008). Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. *Neoplasia* **10**, 511–520.
- [295] Golan M, Hizi A, Resau JH, Yaal-Hahoshen N, Reichman H, Keydar I, and Tsarfay I (2008). Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker. *Neoplasia* **10**, 521–533.
- [296] Noshio K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, and Ogino S (2008). PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. *Neoplasia* **10**, 534–541.
- [297] Naderi A and Hughes-Davies L (2008). A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. *Neoplasia* **10**, 542–548.
- [298] Nazarenko I, Marhaba R, Reich E, Voronov E, Vitacolonna M, Hildebrand D, Elter E, Rajasagi M, Apte RN, and Zoller M (2008). Tumorigenicity of IL-1 α - and IL-1 β -deficient fibrosarcoma cells. *Neoplasia* **10**, 549–562.
- [299] Gu P, Xing X, Tanzer M, Rocken C, Weichert W, Ivanauskas A, Pross M, Peitz U, Malfetheriner P, Schmid RM, et al. (2008). Frequent loss of TIMP-3 expression in progression of esophageal and gastric adenocarcinomas. *Neoplasia* **10**, 563–572.
- [300] Mijatovic T, Mahieu T, Bruyere C, De Neve N, Dewelle J, Simon G, Dehoux MJ, van der Aar E, Haibe-Kains B, Bontempi G, et al. (2008). UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. *Neoplasia* **10**, 573–586.
- [301] Zuco V and Zunino F (2008). Cyclic pifithrin- α sensitizes wild type p53 tumor cells to anticancer tubule agent-induced apoptosis. *Neoplasia* **10**, 587–596.
- [302] Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, and Keshamouni VG (2008). Chemotherapeutic drugs induce PPAR- γ expression and show sequence-specific synergy with PPAR- γ ligands in inhibition of non-small cell lung cancer. *Neoplasia* **10**, 597–603.
- [303] Baia GS, Stifani S, Kimura ET, McDermott MW, Pieper RO, and Lal A (2008). Notch activation is associated with tetraploidy and enhanced chromosomal instability in meningiomas. *Neoplasia* **10**, 604–612.
- [304] Volk LD, Flister MJ, Bivens CM, Stutzman A, Desai N, Trieu V, and Ran S (2008). Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. *Neoplasia* **10**, 613–623.
- [305] Rinnab L, Schutz SV, Diesch J, Schmid E, Kufer R, Hautmann RE, Spindler KD, and Cronauer MV (2008). Inhibition of glycogen synthase kinase-3 in androgen-responsive prostate cancer cell lines: are GSK inhibitors therapeutically useful? *Neoplasia* **10**, 624–634.
- [306] Toma MI, Gresser M, Herr A, Aust DE, Meyer A, Hoefling C, Fuessel S, Wuttig D, Wirth MP, and Baretton GB (2008). Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10K single nucleotide polymorphism mapping array. *Neoplasia* **10**, 634–642.
- [307] Privette LM, Weier JF, Nguyen HN, Yu X, and Petty EM (2008). Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. *Neoplasia* **10**, 643–652.
- [308] Siwko SK, Bu W, Gutierrez C, Lewis B, Jechlinger M, Schaffhausen B, and Li Y (2008). Lentivirus-mediated oncogene introduction into mammary cells *in vivo* induces tumors. *Neoplasia* **10**, 653–662, 651 p following 662.
- [309] Missbach-Guentner J, Dullin C, Kimmina S, Zientkowska M, Domeyer-Missbach M, Malz C, Grabbe E, Stuhmer W, and Alves F (2008). Morphologic changes of mammary carcinomas in mice over time as monitored by flat-panel detector volume computed tomography. *Neoplasia* **10**, 663–673.
- [310] Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, et al. (2008). High expression of HIF1 α is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. *Neoplasia* **10**, 674–679.
- [311] Ahlquist T, Bottillo I, Danielsen SA, Meling GI, Rognum TO, Lind GE, Dallapiccola B, and Lothe RA (2008). RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. *Neoplasia* **10**, 680–686, 682 p following 686.
- [312] Koletsis T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, and Kotoula V (2008). A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. *Neoplasia* **10**, 687–696.
- [313] Ueno K, Hiura M, Suehiro Y, Hazama S, Hirata H, Oka M, Imai K, Dahiya R, and Hinoda Y (2008). Frizzled-7 as a potential therapeutic target in colorectal cancer. *Neoplasia* **10**, 697–705.
- [314] Ruddell A, Harrell MI, Minoshima S, Maravilla KR, Iritani BM, White SW, and Partridge SC (2008). Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow. *Neoplasia* **10**, 706–713, 701 p following 713.
- [315] Rambow F, Piton G, Bouet S, Leplat JJ, Baulande S, Marrau A, Stam M, Horak V, and Vincent-Naulleau S (2008). Gene expression signature for spontaneous cancer regression in melanoma pigs. *Neoplasia* **10**, 714–726, 711 p following 726.

- [316] Brurberg KG, Gaustad JV, Mollatt CS, and Rofstad EK (2008). Temporal heterogeneity in blood supply in human tumor xenografts. *Neoplasia* **10**, 727–735.
- [317] Yu LJ, Wu ML, Li H, Chen XY, Wang Q, Sun Y, Kong QY, and Liu J (2008). Inhibition of STAT3 expression and signaling in resveratrol-differentiated medulloblastoma cells. *Neoplasia* **10**, 736–744.
- [318] Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, and Gillies RJ (2008). Regulation of the Warburg effect in early-passage breast cancer cells. *Neoplasia* **10**, 745–756.
- [319] Potter N, Karakoula A, Phipps KP, Harkness W, Hayward R, Thompson DN, Jacques TS, Harding B, Thomas DG, Palmer RW, et al. (2008). Genomic deletions correlate with underexpression of novel candidate genes at six loci in pediatric pilocytic astrocytoma. *Neoplasia* **10**, 757–772.
- [320] Mellone M, Rinaldi C, Massimi I, Petroni M, Veschi V, Talora C, Truffa S, Stabile H, Frati L, Screpanti I, et al. (2008). Human papilloma virus–dependent HMGA1 expression is a relevant step in cervical carcinogenesis. *Neoplasia* **10**, 773–781.
- [321] Colby JK, Klein RD, McArthur MJ, Conti CJ, Kiguchi K, Kawamoto T, Riggs PK, Pavone AI, Sawicki J, and Fischer SM (2008). Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. *Neoplasia* **10**, 782–796.
- [322] Hall CL, Dubyk CW, Riesenberger TA, Shein D, Keller ET, and van Golen KL (2008). Type I collagen receptor ($\alpha_2\beta_1$) signaling promotes prostate cancer invasion through RhoC GTPase. *Neoplasia* **10**, 797–803.
- [323] Levkoff LH, Marshall GP II, Ross HH, Caldeira M, Reynolds BA, Cakiroglu M, Mariani CL, Streit WJ, and Laywell ED (2008). Bromodeoxyuridine inhibits cancer cell proliferation *in vitro* and *in vivo*. *Neoplasia* **10**, 804–816.
- [324] Nevo I, Sagi-Assif O, Edry Botzer L, Amar D, Maman S, Kariv N, Leider-Trejo LE, Savelyeva L, Schwab M, Yron I, et al. (2008). Generation and characterization of novel local and metastatic human neuroblastoma variants. *Neoplasia* **10**, 816–827.
- [325] Liu X, Shi Y, Woods KW, Hessler P, Kroeger P, Wilsbacher J, Wang J, Wang JY, Li C, Li Q, et al. (2008). Akt inhibitor a-443654 interferes with mitotic progression by regulating aurora kinase expression. *Neoplasia* **10**, 828–837.
- [326] Williams PD, Lee JK, and Theodorescu D (2008). Molecular credentialing of rodent bladder carcinogenesis models. *Neoplasia* **10**, 838–846.
- [327] Wang J, Yu W, Cai Y, Ren C, and Ittmann MM (2008). Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. *Neoplasia* **10**, 847–856.
- [328] Bhattacharya A, Toth K, Durrani FA, Cao S, Slocum HK, Chintala S, and Rustum YM (2008). Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts. *Neoplasia* **10**, 857–865.
- [329] Hollander MC, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR, and Dennis PA (2008). Strain-specific spontaneous and NNK-mediated tumorigenesis in *Pten*^{+/-} mice. *Neoplasia* **10**, 866–872.
- [330] Hetschko H, Voss V, Senft C, Seifert V, Prehn JH, and Kogel D (2008). BH3 mimetics reactivate autophagic cell death in anoxia-resistant malignant glioma cells. *Neoplasia* **10**, 873–885.
- [331] Isenberg JS, Hyodo F, Ridnour LA, Shannon CS, Wink DA, Krishna MC, and Roberts DD (2008). Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. *Neoplasia* **10**, 886–896.
- [332] Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Sun J, et al. (2008). Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. *Neoplasia* **10**, 897–907.
- [333] Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, Cheng AS, Yan PS, Davuluri RV, Huang TH, et al. (2008). Aberrant transforming growth factor β_1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. *Neoplasia* **10**, 908–919.
- [334] Bonte D, Lindvall C, Liu H, Dykema K, Furge K, and Weinreich M (2008). Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. *Neoplasia* **10**, 920–931.
- [335] Okazaki T, Ebihara S, Asada M, Yamada S, Niu K, and Arai H (2008). Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. *Neoplasia* **10**, 932–939.
- [336] Genin O, Rechavi G, Nagler A, Ben-Itzhak O, Nazemi KJ, and Pines M (2008). Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment? *Neoplasia* **10**, 940–948.
- [337] El Sheikh SS, Romanska HM, Abel P, Domin J, and Lalani el N (2008). Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer—a pilot study. *Neoplasia* **10**, 949–953.
- [338] Scheper MA, Shirliff ME, Meiller TF, Peters BM, and Jabra-Rizk MA (2008). Farnesol, a fungal quorum-sensing molecule triggers apoptosis in human oral squamous carcinoma cells. *Neoplasia* **10**, 954–963.
- [339] Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, and Wong KK (2008). Clusterin interacts with paclitaxel and confer paclitaxel resistance in ovarian cancer. *Neoplasia* **10**, 964–972.
- [340] Grochola LF, Greither T, Taubert HW, Moller P, Knippschild U, Udelnow A, Henne-Bruns D, and Wurl P (2008). Prognostic relevance of hTERT mRNA expression in ductal adenocarcinoma of the pancreas. *Neoplasia* **10**, 973–976.
- [341] Chen T, Tang XD, Wan Y, Chen L, Yu ST, Xiong Z, Fang DC, Liang GP, and Yang SM (2008). HLA-A2–restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy. *Neoplasia* **10**, 977–986.
- [342] Ryzhov S, Novitskiy SV, Zaynagudinov R, Goldstein AE, Carbone DP, Biaggioni I, Dikov MM, and Feoktistov I (2008). Host A(2B) adenosine receptors promote carcinoma growth. *Neoplasia* **10**, 987–995.
- [343] Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thuroff JW, Vessella RL, Cher ML, et al. (2008). C-kit and its ligand stem cell factor: potential contribution to prostate cancer bone metastasis. *Neoplasia* **10**, 996–1003.
- [344] Liu B, Yu HM, Huang J, and Hsu W (2008). Co-opted JNK/SAPK signaling in Wnt/ β -catenin–induced tumorigenesis. *Neoplasia* **10**, 1004–1013.
- [345] Kischel P, Guillonau F, Dumont B, Bellahcene A, Stresing V, Clezardin P, De Pauw EA, and Castronovo V (2008). Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. *Neoplasia* **10**, 1014–1020.
- [346] Weichert W, Denkert C, Noske A, Darb-Esfahani S, Dietel M, Kalloger SE, Huntsman DG, and Kobel M (2008). Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. *Neoplasia* **10**, 1021–1027.
- [347] Zhu Q, Tannenbaum S, Hegde P, Kane M, Xu C, and Kurtzman SH (2008). Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization. *Neoplasia* **10**, 1028–1040.
- [348] de Haas EC, di Pietro A, Simpson KL, Meijer C, Suurmeijer AJ, Lancashire LJ, Cummings J, de Jong S, de Vries EG, Dive C, et al. (2008). Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. *Neoplasia* **10**, 1041–1048.
- [349] Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, et al. (2008). Decoy receptor 3 is a prognostic factor in renal cell cancer. *Neoplasia* **10**, 1049–1056.
- [350] Bayani J, Paderova J, Murphy J, Rosen B, Zielenska M, and Squire JA (2008). Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. *Neoplasia* **10**, 1057–1065.
- [351] Perez JM, Grimm J, Josephson L, and Weissleder R (2008). Integrated nanosensors to determine levels and functional activity of human telomerase. *Neoplasia* **10**, 1066–1072.
- [352] Allen CE, Du J, Jiang B, Huang Q, Yakovich AJ, and Barnard JA (2008). Transformation by oncogenic Ras expands the early genomic response to transforming growth factor β in intestinal epithelial cells. *Neoplasia* **10**, 1073–1082.
- [353] Romer MU, Larsen L, Offenberg H, Brunner N, and Lademann UA (2008). Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. *Neoplasia* **10**, 1083–1091.
- [354] Said NA, Elmarakby AA, Imig JD, Fulton DJ, and Motamed K (2008). SPARC ameliorates ovarian cancer–associated inflammation. *Neoplasia* **10**, 1092–1104.
- [355] Das B, Antoon R, Tsuchida R, Lotfi S, Morozova O, Farhat W, Malkin D, Koren G, Yeger H, and Baruchel S (2008). Squalene selectively protects mouse bone marrow progenitors against cisplatin and carboplatin–induced cytotoxicity *in vivo* without protecting tumor growth. *Neoplasia* **10**, 1105–1119.
- [356] Glogowska A, Pyka J, Kehlen A, Los M, Perumal P, Weber E, Cheng SY, Hoang-Vu C, and Klonisch T (2008). The cytoplasmic domain of proEGF negatively regulates motility and elastolytic activity in thyroid carcinoma cells. *Neoplasia* **10**, 1120–1130.
- [357] Lincz LF, Mudge LM, Scorgie FE, Sakoff JA, Hamilton CS, and Seldon M (2008). Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the β deletion variant. *Neoplasia* **10**, 1131–1137.

- [358] Li Q, Feldman RA, Radhakrishnan VM, Carey S, and Martinez JD (2008). Hsf1 is required for the nuclear translocation of p53 tumor suppressor. *Neoplasia* **10**, 1138–1145.
- [359] Mehta GU, Shively SB, Duong H, Tran MG, Moncrief TJ, Smith JH, Li J, Edwards NA, Lonser RR, Zhuang Z, et al. (2008). Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease. *Neoplasia* **10**, 1146–1153.
- [360] Schmieder M, Wolf S, Danner B, Stoehr S, Juchems MS, Wuerl P, Henne-Bruns D, Knippschild U, Hasel C, and Kramer K (2008). p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome. *Neoplasia* **10**, 1154–1162.
- [361] Stasinopoulos I, Mori N, and Bhujwala ZM (2008). The malignant phenotype of breast cancer cells is reduced by COX-2 silencing. *Neoplasia* **10**, 1162–1169.
- [362] Ashkenazi R, Gentry SN, and Jackson TL (2008). Pathways to tumorigenesis—modeling mutation acquisition in stem cells and their progen. *Neoplasia* **10**, 1170–1182.
- [363] Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquère S, Ripoche H, Khabir A, Tsao TW, Bosq J, Lo KW, et al. (2008). Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to toll-like receptor 3-mediated apoptosis. *Neoplasia* **10**, 1183–1194.
- [364] Menschikowski M, Hagelgans A, Kostka H, Eisenhofer G, and Siegert G (2008). Involvement of epigenetic mechanisms in the regulation of secretory phospholipase A2 expression in Jurkat leukemia cells. *Neoplasia* **10**, 1195–1203.
- [365] Striedinger K, VandenBerg SR, Baia GS, McDermott MW, Gutmann DH, and Lal A (2008). The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. *Neoplasia* **10**, 1204–1212.
- [366] Jones GN, Tep C, Towns WH II, Mihai G, Tonks ID, Kay GF, Schmalbrock PM, Stemmer-Rachamimov AO, Yoon SO, and Kirschner LS (2008). Tissue-specific ablation of Prkrla causes schwannomas by suppressing NF protein production. *Neoplasia* **10**, 1213–1221.
- [367] Roschke AV, Glebov OK, Lababidi S, Gehlhaus KS, Weinstein JN, and Kirsch IR (2008). Chromosomal instability is associated with higher expression of genes implicated in EMT, cancer invasiveness and metastasis, and lower expression of genes involved in cell cycle checkpoints, DNA repair and chromatin maintenance. *Neoplasia* **10**, 1222–1230.
- [368] Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao B, Dunleavy R, Mann GJ, Kefford RF, and Rizos H (2008). *p16^{INK4a}* expression and absence of *B-RAF* are independent predictors of chemosensitivity in melanoma tumors. *Neoplasia* **10**, 1231–1239.
- [369] Corsino PE, Davis BJ, Nørgaard PH, Parker NNT, Law M, Dunn W, and Law BK (2008). Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component. *Neoplasia* **10**, 1240–1252.
- [370] Gorringe KL, Choong DYH, Williams LH, Ramakrishna M, Sridhar A, Qiu W, Bearfoot JL, and Campbell IG (2008). Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. *Neoplasia* **10**, 1253–1258.
- [371] Landen CN, Kim T, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennings NB, Kinch MS, et al. (2008). Tumor-selective response to antibody-mediated targeting of $\alpha_v\beta_3$ integrin in ovarian cancer. *Neoplasia* **10**, 1259–1267.
- [372] Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, and Weiss WA (2008). Chemotherapy induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. *Neoplasia* **10**, 1268–1274.
- [373] Liu F, Chen Z, Wang J, Shao X, Cui Z, Yang C, Zhu Z, and Xiong D (2008). Overexpression of cell-surface cytokeratin 8 in multidrug-resistant MCF-7/MX cells enhances cell adhesion to the extracellular matrix. *Neoplasia* **10**, 1275–1284.
- [374] Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, et al. (2008). Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. *Neoplasia* **10**, 1285–1294.
- [375] Schneider A, Younis RH, and Gutkind JS (2008). Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma. *Neoplasia* **10**, 1295–1302.
- [376] Elia U and Flescher E (2008). PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate towards sarcoma cells. *Neoplasia* **10**, 1303–1313.
- [377] Mathieu V, Neve ND, Mercier ML, Dewelle J, Gaussin J, Dehaux M, Kiss R, and LeFranc F (2008). Combining bevacizumab with temozolomide increases the anti-tumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. *Neoplasia* **10**.
- [378] Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, and Malatesta P (2008). Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. *Neoplasia* **10**.
- [379] Jiang W, Xiang C, Cazacu S, Brodie C, and Mikkelsen T (2008). Insulin-like growth factor binding protein 7 (IGFBP-7) mediates glioma cell growth and migration. *Neoplasia* **10**.
- [380] Li Q and Mattingly RR (2008). Restoration of E-cadherin cell-cell junctions requires both expression of E-cadherin and suppression of ERK MAP kinase activation in Ras-transformed breast epithelial cells. *Neoplasia* **10**.
- [381] Rowe A, Weiske J, Kramer TS, Huber O, and Jackson P (2008). Phorbol ester enhances KAI1 transcription by recruiting Tip60/Pontin complexes. *Neoplasia* **10**.
- [382] Sprenger CCT, Drivdahl RH, Woodke LB, Eyman D, Reed MR, Carter WG, and Plymate S (2008). Senescence-induced alterations of laminin chain expression modulate tumorigenicity of prostate cancer cells. *Neoplasia* **10**.
- [383] Ogbomo H, Michaelis M, Klassert D, Doerr HW, and Cinal J (2008). Resistance of cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cells. *Neoplasia* **10**.
- [384] Chen JY, Hung C, Huang K, Chen Y, Liu S, Chiang W, Chen H, Yen C, Wu Y, Ko J, et al. (2008). Src family kinases mediate betel quid-induced oral cancer cell motility and could be a biomarker for early invasion in oral squamous cell carcinoma. *Neoplasia* **10**.
- [385] Michael LE, Westerman BA, Ermilov AN, Wang A, Ferris J, Liu J, Blom M, Ellison DW, Lohuizen MV, and Dlugosz A (2008). Bmi1 is required for Hedgehog-pathway driven medulloblastoma expansion. *Neoplasia* **10**.
- [386] Grange C, Stefania L, Cavallo F, Camussi G, and Bussolati B (2008). Sca-1 identifies the tumor initiating cells in mammary tumors of BALB-NEUT transgenic mice. *Neoplasia* **10**.
- [387] Kim HK, Zhang H, Li H, Wu T, Swisher S, He D, Wu L, Xu J, Elmetts CA, Athar M, et al. (2008). Slit2 inhibits the growth and metastasis of fibrosarcoma and squamous cell carcinoma. *Neoplasia* **10**.
- [388] Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, et al. (2008). Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. *Neoplasia* **10**.
- [389] Tamimi Y, Ekuere U, Laughton N, Milanovic A, and Grundy P (2008). *WNT5A* is regulated by *PAX2* and may be involved in blastemal predominant Wilms tumorigenesis. *Neoplasia* **10**.
- [390] Tilborg GAF, Mulder WJM, Schaft DKJ, Reutelingsperger CPM, Griffioen AW, Strijkers GJ, and Nicolay K (2008). Improved MR molecular imaging of tumor angiogenesis by avidin-induced clearance of non-bound bimodal liposomes. *Neoplasia* **10**.
- [391] Triplett AA, Montagna CM, and Wagner K (2008). A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis. *Neoplasia* **10**.